Bristol Myers Squibb (BMS) and Immatics will develop up to seven cancer cell therapies by launching a new partnership and expanding a three-year-old collaboration inked by BMS predecessor Celgene, the ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...

Arsenal Bio is jumping headfirst into the cell therapy arena, and its latest fundraising haul, backed in part by Bristol Myers Squibb, is making a significant splash. The company has reeled in $220 ...

Bristol Myers Squibb (BMS) drug Abecma was the first FDA-approved CAR T-cell therapy for multiple myeloma, but like other drugs in its class, the treatment’s serious side effect risks limit its use to ...

With two cell therapies approved and three more in its pipeline, Bristol Myers Squibb is working to beef up its manufacturing capabilities for the complex, personalized, one-and-done medicines. On ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...

At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...